Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13940206 | 0.87 | CXCR4 (0.38) | EIF2AK2JAK2PIK3C3MKNK1MAPK9 | |
| SCHEMBL8228196 | 0.79 | BRAF (0.57) | BRAFMAPK9 | |
| SCHEMBL2639622 | 0.79 | BRAF (0.43) | BRAFJAK2JAK1TYK2STAT3 | |
| SCHEMBL2640189 | 0.78 | BRAF (0.40) | BRAFEIF2AK2PIK3C3 | |
| SCHEMBL2640080 | 0.78 | BRAF (0.40) | BRAFMKNK1 | |
| SCHEMBL2639939 | 0.77 | BRAF (0.38) | BRAFEIF2AK2 | |
| SCHEMBL2957753 | 0.77 | BRAF (0.38) | BRAFEIF2AK2MAPK9 | |
| SCHEMBL2639692 | 0.77 | BRAF (0.38) | BRAFPIK3C3 | |
| SCHEMBL13940248 | 0.76 | BRAF (0.34) | BRAFJAK2JAK1TYK2STAT3 | |
| SCHEMBL2639843 | 0.76 | BRAF (0.41) | BRAFEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | BRAF 1/4885EIF2AK2 3105/4885JAK2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.